Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease

NCT03295786 is registered in ClinicalTrials.gov with Herantis Pharma Plc. as lead sponsor.

NCT NCT03295786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03295786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease
Lead sponsor
Herantis Pharma Plc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 26, 2017
Completion date
December 19, 2019
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brain diseases, movement disorders, nervous system diseases, neurodegenerative diseases, parkinson disease